IL-2-mediated_JJ
cell_NN
cycle_NN
progression_NN
and_CC
inhibition_NN
of_IN
apoptosis_NN
does_VBZ
not_RB
require_VB
NF-kappa_NN
B_NN
or_CC
activating_VBG
protein-1_NN
activation_NN
in_IN
primary_JJ
human_JJ
T_NN
cells_NNS
._.

The_DT
IL-2_NN
growth_NN
hormone_NN
is_VBZ
the_DT
major_JJ
growth_NN
factor_NN
of_IN
activated_VBN
T_NN
lymphocytes_NNS
during_IN
a_DT
developing_VBG
immune_JJ
response_NN
._.

IL-2_NN
is_VBZ
required_VBN
not_RB
only_RB
for_IN
cell_NN
cycle_NN
progression_NN
but_CC
also_RB
to_TO
protect_VB
Ag-activated_JJ
T_NN
cells_NNS
from_IN
programmed_VBN
cell_NN
death_NN
._.

In_IN
several_JJ
cell_NN
types_NNS
,_,
activation_NN
of_IN
NF-kappa_NN
B_NN
and\/or_CC
activating_VBG
protein-1_NN
-LRB-_-LRB-
AP-1_NN
-RRB-_-RRB-
has_VBZ
been_VBN
demonstrated_VBN
to_TO
be_VB
extremely_RB
important_JJ
in_IN
blocking_VBG
apoptosis_NN
._.

To_TO
determine_VB
whether_IN
either_DT
or_CC
both_DT
of_IN
these_DT
transcription_NN
factors_NNS
are_VBP
involved_VBN
in_IN
cell_NN
survival_NN
or_CC
cell_NN
cycle_NN
progression_NN
in_IN
response_NN
to_TO
IL-2_NN
,_,
primary_JJ
human_JJ
T_NN
cells_NNS
responsive_JJ
to_TO
the_DT
growth_NN
factor_NN
were_VBD
analyzed_VBN
for_IN
NF-kappa_NN
B_NN
and_CC
AP-1_NN
activation_NN
._.

The_DT
current_JJ
study_NN
clearly_RB
demonstrates_VBZ
that_IN
IL-2_NN
does_VBZ
not_RB
induce_VB
I_NN
kappa_NN
B_NN
alpha_NN
degradation_NN
or_CC
NF-kappa_NN
B_NN
activation_NN
in_IN
primary_JJ
human_JJ
T_NN
cells_NNS
that_WDT
respond_VBP
to_TO
IL-2_NN
by_IN
entering_VBG
the_DT
cell_NN
cycle_NN
and_CC
avoiding_VBG
apoptosis_NN
._.

Similarly_RB
,_,
IL-2_NN
neither_CC
activates_VBZ
JNK_NN
nor_CC
increases_VBZ
AP-1_NN
binding_NN
activity_NN
to_TO
a_DT
consensus_NN
o-tetradecanoylphorbol_NN
13-acetate_NN
-LRB-_-LRB-
TPA_NN
-RRB-_-RRB-
response_NN
element_NN
._.

On_IN
the_DT
other_JJ
hand_NN
,_,
the_DT
growth_NN
factor_NN
does_VBZ
induce_VB
the_DT
activation_NN
of_IN
STAT3_NN
and_CC
STAT5_NN
in_IN
these_DT
cells_NNS
,_,
as_IN
has_VBZ
been_VBN
previously_RB
demonstrated_VBN
._.

These_DT
data_NNS
show_VBP
that_IN
neither_CC
NF-kappa_NN
B_NN
nor_CC
AP-1_NN
activation_NN
is_VBZ
required_VBN
for_IN
IL-2-mediated_JJ
survival_NN
or_CC
cell_NN
cycle_NN
progression_NN
in_IN
activated_VBN
primary_JJ
human_JJ
T_NN
cells_NNS
._.

